Sugi Predict

Sugi Predict / Compounds / SCHEMBL140922

SCHEMBL140922

SCHEMBL140922

C[C@H](N)c1ccc(Cl)cc1

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ ADRB2 P07550 1/20 1.00
▸ SLC6A3 Q01959 4/20 0.50
▸ SLC6A2 P23975 1/20 0.50
▸ LMNA P02545 3/20 0.48
▸ TP53 P04637 2/20 0.48
▸ HTT P42858 1/20 0.48
▸ IDO1 P14902 3/20 0.46
▸ TDO2 P48775 3/20 0.46
▸ TSHR P16473 2/20 0.46
▸ MAPK1 P28482 2/20 0.46
▸ HIF1A Q16665 2/20 0.46
▸ TDP1 Q9NUW8 2/20 0.46
▸ SLC6A4 P31645 4/20 0.45
▸ PDE2A O00408 1/20 0.45
▸ CYP2A6 P11509 1/20 0.44
▸ HPGD P15428 1/20 0.44
▸ AOC3 Q16853 1/20 0.42
▸ BRD4 O60885 1/20 0.41
▸ CYP19A1 P11511 1/20 0.41
▸ FFAR2 O15552 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL138590 1.00 ADRB2 (1.00) ADRB2SLC6A3SLC6A2LMNATP53
SCHEMBL177057 1.00 ADRB2 (1.00) ADRB2SLC6A3SLC6A2LMNATP53
Bromide SCHEMBL28703130 0.97 ADRB2 (0.95) ADRB2SLC6A3SLC6A2LMNATP53
Iodide SCHEMBL29127483 0.97 ADRB2 (0.95) ADRB2SLC6A3SLC6A2LMNATP53
Hydrochloric Acid SCHEMBL2459100 0.97 ADRB2 (0.95) ADRB2SLC6A3SLC6A2LMNATP53
Hydrochloric Acid SCHEMBL25383293 0.97 ADRB2 (0.95) ADRB2SLC6A3SLC6A2LMNATP53
Hydrochloric Acid SCHEMBL1924682 0.97 ADRB2 (0.95) ADRB2SLC6A3SLC6A2LMNATP53
SCHEMBL10804179 0.93 ADRB2 (0.86) ADRB2SLC6A3SLC6A2LMNATP53
SCHEMBL1314596 0.85 ADRB2 (0.72) ADRB2LMNAHTTTSHRHIF1A
SCHEMBL17540834 0.82 ADRB2 (0.70) ADRB2LMNAHTTIDO1HIF1A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 681 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2025262194-A1 PHARMACEUTICAL FORMULATIONS OF ATX INHIBITORS IONCTURA B.V. (NL) 2025-12-26 — — WO claimed
US-20250387385-A1 TREATMENT FOR GLOMERULAR DISEASES ZYDUS LIFESCIENCES LIMITED (IN) 2025-12-25 — — US claimed
EP-4565233-A1 TREATMENT FOR APLASTIC ANEMIA (AA) Zydus Lifesciences Limited (IN) 2025-06-11 — — EP claimed
EP-4539934-A1 TREATMENT FOR GLOMERULAR DISEASES Zydus Lifesciences Limited (IN) 2025-04-23 — — EP claimed
US-20250078176-A1 ENVIRONMENTAL ATTRIBUTES FOR NITROGEN CONTAINING CHEMICALS BASF SE (DE) 2025-03-06 — — US claimed
CN-118435582-A Environmental attributes of nitrogen-containing chemicals 巴斯夫欧洲公司 2024-08-02 — — CN claimed
CN-118064400-B S-selective omega-aminotransferase mutant with high catalytic activity, and construction method and application thereof 中国科学院苏州生物医学工程技术研究所 2024-06-25 — — CN claimed
US-20240173314-A1 TREATMENT OF SICKLE CELL ANAEMIA ZYDUS LIFESCIENCES LTD. (IN) 2024-05-30 — — US claimed
CN-118064400-A S-selective omega-aminotransferase mutant with high catalytic activity, and construction method and application thereof 中国科学院苏州生物医学工程技术研究所 2024-05-24 — — CN claimed
WO-2024028744-A1 TREATMENT FOR APLASTIC ANEMIA (AA) ZYDUS LIFESCIENCES LIMITED (IN) 2024-02-08 — — WO claimed
EP-2069320-A2 PROCESS FOR THE SYNTHESIS OF RAMELTEON AND ITS INTERMEDIATES Teva Pharmaceutical Industries Ltd. (IL) 2009-06-17 — — EP claimed
US-20090069581-A1 PROCESS FOR THE SYNTHESIS OF RAMELTEON AND ITS INTERMEDIATES TEVA PHARMACEUTICAL INDUSTRIES LTD. (IL) 2009-03-12 — — US claimed
WO-2008151170-A2 PROCESS FOR THE SYNTHESIS OF RAMELTEON AND ITS INTERMEDIATES TEVA PHARMACEUTICAL INDUSTRIES LTD. (IL) 2008-12-11 — — WO claimed
WO-2008117955-A1 PROCESS FOR PREPARING OF 2'-DEOXY-2'2'-DIFLUOROCYTIDINE DONGWOO SYNTECH CO., LTD. (KR) 2008-10-02 — — WO claimed
EP-1124782-B1 METHOD FOR RACEMATE SPLITTING OF 2-HYDROXYPROPIONIC ACIDS ABBOTT GMBH & CO KG (DE) 2004-01-02 — — EP claimed
US-6559338-B1 Method for racemate splitting of 2-hydroxypropionic acids BASF AKTIENGESELLSCHAFT (DE) 2003-05-06 — — US claimed
EP-0923534-B1 PROCESS FOR PREPARING RACEMIC PHENETHYLAMINES BAYER AG (DE) 2000-10-04 — — EP claimed
US-6046351-A Process for preparing racemic phenethylamines BAYER AKTIENGESELLSCHAFT (DE) 2000-04-04 — — US claimed
CN-1226228-A Process for preparing preparing racemic phenethylamines BAYER AG (DE) 1999-08-18 — — CN claimed
US-5144077-A PROCESS FOR WORKING UP THE CRYSTALLIZATION MOTHER LIQUOR FROM THE RESOLUTION OF THE RACEMATE OF 1-(4-CHLOROPHENYL)-ETHYLAMINE BAYER AKTIENGESELLSCHAFT (DE) 1992-09-01 — — US claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250387385-A1 TREATMENT FOR GLOMERULAR DISEASES SSB, GRN, ALB ADRB2 4535/4885SLC6A3 891/4885SLC6A2 946/4885
US-20090069581-A1 PROCESS FOR THE SYNTHESIS OF RAMELTEON AND ITS INTERMEDIATES CYP2B6, UGT1A6, CYP2A6 ADRB2 1661/4885SLC6A3 1207/4885SLC6A2 893/4885
US-20240173314-A1 TREATMENT OF SICKLE CELL ANAEMIA HBG1, HBB, HBG2 ADRB2 1044/4885SLC6A3 2003/4885SLC6A2 914/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.